Zeer Aldevron / intent / aldevron

Aldevron

1001-5000 employees·Fargo, North Dakota, United States·aldevron.com

Observed, not inferred · updated weekly

Buying intent

28 tracked signals | Top 15 topics are below | Sales and Marketing are carrying most of it.

23signals · 30 days
20topics tracked
71.43%attributed to a team

Attention by team

LinkedIn activity, by team

Where Aldevron's own people are actually spending their attention, by team, by topic. Bands run Low to High against the busiest pairing on this page, and each cell also shows how much of that team's own activity it represents.

Pharmaceutical
Gene Therapy
Cell Therapy
Data Center
Healthcare Industry
Strategy Alignment
Sales
High38% of team Sales to Pharmaceutical: High, 38% of this team's signals
High25% of team Sales to Gene Therapy: High, 25% of this team's signals
Medium13% of team Sales to Cell Therapy: Medium, 13% of this team's signals
Sales to Data Center: no signal
Medium13% of team Sales to Healthcare Industry: Medium, 13% of this team's signals
Medium13% of team Sales to Strategy Alignment: Medium, 13% of this team's signals
Marketing
Marketing to Pharmaceutical: no signal
Marketing to Gene Therapy: no signal
Medium100% of team Marketing to Cell Therapy: Medium, 100% of this team's signals
Marketing to Data Center: no signal
Marketing to Healthcare Industry: no signal
Marketing to Strategy Alignment: no signal
Operations
Operations to Pharmaceutical: no signal
Operations to Gene Therapy: no signal
Operations to Cell Therapy: no signal
Medium100% of team Operations to Data Center: Medium, 100% of this team's signals
Operations to Healthcare Industry: no signal
Operations to Strategy Alignment: no signal
Others
Medium25% of team Others to Pharmaceutical: Medium, 25% of this team's signals
Medium25% of team Others to Gene Therapy: Medium, 25% of this team's signals
Medium25% of team Others to Cell Therapy: Medium, 25% of this team's signals
Medium25% of team Others to Data Center: Medium, 25% of this team's signals
Others to Healthcare Industry: no signal
Others to Strategy Alignment: no signal
LowMediumHigh·  banded against the busiest pairing on this page

Topics being researched

30-day window

Every tracked topic, ranked by volume, not by our guess at what matters. Confidence is the classifier's own certainty that a signal belongs where we've filed it.

Pharmaceutical
LinkedIn
High volume
98%
last
24d ago
Gene Therapy
LinkedIn
High volume
98%
last
24d ago
Cell Therapy
LinkedIn
High volume
98%
last
19d ago
Data Center
LinkedIn
Medium volume
96%
last
19d ago
Healthcare Industry
LinkedIn
Low volume
98%
last
25d ago
Strategy Alignment
LinkedIn
Low volume
98%
last
25d ago
Red Team
LinkedIn
Low volume
98%
last
17d ago
Artificial Intelligence
LinkedIn
Low volume
96%
last
19d ago
Event Management
LinkedIn
Low volume
98%
last
18d ago
Vulnerability Assessment
LinkedIn
Low volume
96%
last
17d ago
CAR-T Cell Therapy
LinkedIn
Low volume
92%
last
24d ago
Drug Development
LinkedIn
Low volume
98%
last
26d ago
Professional Development
LinkedIn
Low volume
94%
last
10d ago
Follow-Up
LinkedIn
Low volume
98%
last
17d ago
Leadership Development
LinkedIn
Low volume
98%
last
10d ago

Need intent for a specific topic or industry?

We track the full taxonomy across every account in the graph — including themes not shown on this page.

Talk to us

Who's active at Aldevron

verified title on file

Titles, seniority and topic straight from each person's own activity, with a LinkedIn link so you can check any of them yourself.

Others6 active
researching Cell Therapy
in
researching Follow-Up
in
Leadershipresearching Pro Bono
in
researching Event Management
in
researching Data Center
in
Leadershipresearching Artificial Intelligence
in
Sales3 active
Senior ICresearching Gene Therapy
in
Senior ICresearching Pharmaceutical
in
Senior ICresearching Professional Development
in
Marketing1 active
Directorresearching Cell Therapy
in
Operations1 active
director, industrial project management
researching Data Center
in
+ 1 more in Operations

See everyone, not just the first 10

11 people across every department at Aldevron, plus a LinkedIn profile link for each.

Primary products / business lines

LinkedIn company profile

Aldevron is proud to be part of Danaher.  Danaher’s science and technology leadership puts Aldevron’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers.  Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock

Top accounts researching Aldevron

names withheld on the public page

These are companies whose own people brought up Aldevron unprompted, not accounts we guessed might be interested. We can't yet tell an implementation partner from a genuine buyer here, names unlock along with the buyer profile below.

6,459 companies · 25,813 people are researching Pharmaceutical

Aldevron's own team shows 4 signals on this topic. No one outside Aldevron has been seen researching the company by name yet — so this is the market it sits in, not a list of its buyers.

  • Gene Therapy675 cos · 1,971 people
  • Cell Therapy523 cos · 1,729 people
Sign up to see which companies →

Buyer profile

company size · seniority

Company size and how senior the people involved are, the two things that decide whether this is a real deal. Competitor overlap isn't computed yet for this account.

Unlock the buyer profile

Company-size breakdown and buyer seniority mix for accounts researching Aldevron.

Company size breakdown
Buyer seniority mix

Sign up to learn more

Create an account to explore buyer insights as they become available.

Sign up to learn more →

Buying committee functions

Employee job titles (LinkedIn)

Sales — 4 people; Marketing — 1 person; Leadership — 1 person

What's been said

public posts mentioning Aldevron

Up to 9 public excerpts naming Aldevron from the past 365 days, across LinkedIn, Reddit, X, YouTube and other public sources.

LinkedIn

Partnerships like this don't happen overnight and they don't move forward without real alignment. At ASGCT, Emma Bjorgum (Aldevron) and Francesca Vitelli (Minaris Advanced Therapies) took a moment to share their excitement. This collaboration is about expanding access to lentiviral plasmids in a way that actually reduces complexity for developers. The goal is simple: make it easier to move from discovery into the clinic with greater consistency, fewer bottlenecks, and materials that are ready to scale when it matters most. #ASGCT #CellAndGeneTherapy #Biomanufacturing #LentiviralVectors

May 2026
LinkedIn

Ex-vivo LVV? In-Vivo LVV? This collaboration between Aldevron and Minaris Advanced Therapies gives our program sponsors access to Off-the-shelf material that is proven in clinical trials and best in class LVV titiers. Why spend the time and money optimizing your LVV packagers..? We have you covered - oh and custom GOI, in Reseach Grade through GMP, of course we have you covered there too! “A World where every cure is possible” - Aldevron

May 2026
LinkedInCell Therapy Manufacturing

Moments like this highlight the importance of scalable, high-quality manufacturing in bringing breakthrough science to life. Honored that Aldevron teams could help accelerate such a meaningful advance. ---- Baby KJ was born with a rare, potentially fatal genetic disease with limited treatment options and significant uncertainty. In response, the world's first personalized CRISPR‑based therapy was designed, manufactured, and administered to him in record time. That effort is why teams from Children's Hospital of Philadelphia, Penn Medicine, University of Pennsylvania Health System, Innovative Genomics Institute, and Danaher Corporation received the ASGCT Catalyst Award this week at #ASGCT2026 . The work moved forward because people across medicine, academia, and industry stayed aligned on one outcome: turning a one‑of‑a‑kind scientific idea into a treatment for a child who needed it now. Doing that required coordination across research, manufacturing, and clinical care, with no precedent and no margin for delay. Danaher Life Sciences businesses Aldevron and Integrated DNA Technologies manufactured key components of this highly complex, personalized gene editing therapy at speed, with Aldevron producing the final drug product. Congratulations to the teams whose collaboration made this possible, and to the broader cell and gene therapy community advancing what can be delivered when expertise, scale, and urgency come together.

May 2026
LinkedInContract Development and Manufacturing Company (CDMO)

The announced partnership with Minaris below, is yet another example how Aldevron is uniquely positioned to support our program sponsors in a way no other CDMO is able, across multiple modalities and quality grades. With the Minaris partnership, Aldevron continues to support LVV / GMCT plasmid needs, from Discovery to Commercialization - No other CDMO has done more RG plasmid lots, and no one has more commercial products supported, outside Aldevron. “A world where every cure is possible” - Aldevron

May 2026
LinkedIn

Looking forward to connecting with all of you at ASGCT. I’m spending time at the Danaher booth (1337) alongside the Aldevron team. These conversations—across research, development, and manufacturing—are where real progress happens and impact is delivered at every stage. If you’re attending, feel free to stop by and say hello. 🔗 https://lnkd.in/ebXajcq2 #ASGCT #GeneTherapy #CellTherapy #ATMP #BiotechEvents

May 2026
LinkedIn

Early decisions in mRNA development have long‑term consequences. Join Aldevron for an upcoming webinar, Start Right. Scale Right: Scaling mRNA Therapeutics from Research‑Grade to cGMP, focused on the inflection points that can either accelerate progress or introduce comparability, regulatory, and scalability challenges. This session will explore: ✅Phase‑appropriate decisions for linear DNA templates, IVT, and analytics ✅Common scale‑up pitfalls such as variability, dsRNA formation, and material mismatches ✅How aligning research‑stage methods with cGMP realities can de‑risk tech transfer and clinical transitions Catch our webinar on May 20. Register now: https://ald.bio/4cvnIOX #mRNA #cGMP #GeneTherapy #Biomanufacturing #ProcessDevelopment

May 2026
LinkedIn

We are thrilled to renew Aldevron’s partnership with Minaris for access to lentiviral plasmids at any stage of development!

May 2026

About this data. Aldevron (aldevron.com). Department attribution is 71.43%; remaining activity is grouped under Others. Updated 2026-10-03T14:00:03.490Z.

Not yet computedPer-team narrative summaries